| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Depreciation | 0 | 0 | ||
| Research and development | 2,192,881 | 2,499,495 | ||
| General and administrative | 1,153,032 | 2,182,289 | ||
| Total operating expenses | 3,345,913 | 4,681,784 | ||
| Operating loss | -3,345,913 | -4,681,784 | ||
| Other income | 2,405 | 6,881 | ||
| Other financing costs | -455,549 | - | ||
| Realized and unrealized loss | -183 | 2 | ||
| Net loss | -3,799,240 | -4,674,901 | ||
| Deemed dividend related to warrant modification | 0 | 0 | ||
| Net loss attributable to common stockholders | -3,799,240 | -4,674,901 | ||
| Net loss per share applicable to common stockholders basic and diluted (in dollars per share) | -5 | -0.17 | ||
| Weighted average number of common shares basic and diluted (in shares) | 760,502 | 27,593,952 | ||
Genprex, Inc. (GNPX)
Genprex, Inc. (GNPX)